HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

James L Abbruzzese Selected Research

Adenocarcinoma

5/2022Differential Effects of Dietary Macronutrients on the Development of Oncogenic KRAS-Mediated Pancreatic Ductal Adenocarcinoma.
11/2020Improved overall survival is still observed in patients receiving delayed adjuvant chemotherapy after pancreaticoduodenectomy for pancreatic adenocarcinoma.
5/2018The Interface of Pancreatic Cancer With Diabetes, Obesity, and Inflammation: Research Gaps and Opportunities: Summary of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop.
1/2017Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience.
1/2017Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer.
9/2015Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma.
5/2014Aberrant expression of p53, p21, cyclin D1, and Bcl2 and their clinicopathological correlation in ampullary adenocarcinoma.
4/2014Transport properties of pancreatic cancer describe gemcitabine delivery and response.
1/2014Treatment sequencing for resectable pancreatic cancer: influence of early metastases and surgical complications on multimodality therapy completion and survival.
12/2013The cost-effectiveness of neoadjuvant chemoradiation is superior to a surgery-first approach in the treatment of pancreatic head adenocarcinoma.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


James L Abbruzzese Research Topics

Disease

142Neoplasms (Cancer)
05/2022 - 01/2002
125Pancreatic Neoplasms (Pancreatic Cancer)
01/2020 - 01/2002
78Adenocarcinoma
05/2022 - 01/2002
24Neoplasm Metastasis (Metastasis)
11/2019 - 01/2003
16Carcinogenesis
05/2022 - 01/2002
16Colorectal Neoplasms (Colorectal Cancer)
01/2010 - 10/2002
11Carcinoma (Carcinomatosis)
06/2012 - 02/2002
10Disease Progression
01/2014 - 07/2004
9Hepatocellular Carcinoma (Hepatoma)
05/2014 - 02/2005
7Inflammation (Inflammations)
05/2022 - 11/2003
7Obesity
02/2021 - 09/2010
6Colonic Neoplasms (Colon Cancer)
01/2021 - 05/2005
5Neutropenia
11/2010 - 01/2002
4Chronic Pancreatitis
01/2017 - 02/2009
4Esophageal Neoplasms (Esophageal Cancer)
05/2012 - 01/2004
4Vomiting
02/2012 - 04/2003
4Liver Neoplasms (Liver Cancer)
06/2011 - 10/2005
4Infections
04/2010 - 01/2003
4Pancreatitis
12/2007 - 02/2003
3Exanthema (Rash)
01/2022 - 04/2003
3Nausea
02/2012 - 04/2003
3Lymphatic Metastasis
01/2012 - 01/2004
3Stomach Neoplasms (Stomach Cancer)
04/2010 - 01/2004
3Fatigue
06/2006 - 04/2003
2Colitis
01/2022 - 01/2005
2Melanoma (Melanoma, Malignant)
01/2021 - 10/2004
2Pancreatic Diseases (Pancreatic Disease)
01/2017 - 12/2004

Drug/Important Bio-Agent (IBA)

36GemcitabineFDA Link
01/2018 - 04/2002
25Proteins (Proteins, Gene)FDA Link
01/2017 - 12/2002
19Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
10/2011 - 12/2002
16NF-kappa B (NF-kB)IBA
07/2008 - 09/2002
15Biomarkers (Surrogate Marker)IBA
01/2021 - 09/2002
15Fluorouracil (Carac)FDA LinkGeneric
03/2016 - 04/2002
14ErbB Receptors (EGF Receptor)IBA
11/2010 - 10/2002
13Pharmaceutical PreparationsIBA
11/2014 - 01/2002
13Transcription Factors (Transcription Factor)IBA
05/2009 - 08/2002
11DNA (Deoxyribonucleic Acid)IBA
11/2014 - 01/2006
10Messenger RNA (mRNA)IBA
03/2009 - 03/2003
9Phosphotransferases (Kinase)IBA
01/2021 - 01/2005
9Cisplatin (Platino)FDA LinkGeneric
10/2013 - 01/2004
9Oxaliplatin (Eloxatin)FDA LinkGeneric
12/2011 - 08/2004
8Cetuximab (Erbitux)FDA Link
01/2018 - 10/2002
8Biological ProductsIBA
07/2008 - 02/2003
7Irinotecan (Camptosar)FDA LinkGeneric
05/2012 - 08/2004
7Capecitabine (Xeloda)FDA Link
08/2011 - 06/2004
7Bortezomib (Velcade)FDA Link
09/2006 - 09/2002
6Bevacizumab (Avastin)FDA Link
01/2018 - 03/2006
6LuciferasesIBA
08/2011 - 05/2006
5Glucose (Dextrose)FDA LinkGeneric
05/2022 - 04/2008
5EnzymesIBA
01/2017 - 11/2002
5Erlotinib Hydrochloride (CP 358,774)FDA Link
10/2013 - 10/2006
5Small Interfering RNA (siRNA)IBA
08/2011 - 03/2006
5Tyrosine Kinase InhibitorsIBA
11/2010 - 07/2005
5Leucovorin (Folinic Acid)FDA Link
04/2010 - 08/2004
5CytokinesIBA
01/2010 - 01/2003
5Antineoplastic Agents (Antineoplastics)IBA
03/2007 - 01/2003
5Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA
11/2005 - 07/2004
4fibroblast growth factor 21IBA
02/2021 - 11/2013
4Insulin (Novolin)FDA Link
05/2014 - 08/2009
4Proteasome Endopeptidase Complex (Proteasome)IBA
02/2014 - 12/2002
4Insulin-Like PeptidesIBA
04/2012 - 10/2006
4tolfenamic acidIBA
01/2011 - 06/2006
4Monoclonal AntibodiesIBA
08/2010 - 05/2004
4LigandsIBA
03/2009 - 10/2002
4CarcinogensIBA
06/2008 - 01/2002
4Codon (Codons)IBA
08/2007 - 01/2002
4Interleukin-8 (Interleukin 8)IBA
01/2005 - 01/2003
4Peptides (Polypeptides)IBA
01/2005 - 12/2002
3Protein Kinases (Protein Kinase)IBA
01/2019 - 07/2007
3InterferonsIBA
09/2013 - 03/2003
3Phosphatidylinositols (Phosphatidylinositol)IBA
07/2010 - 11/2004
3Transcription Factor AP-1 (Transcription Factor AP 1)IBA
05/2009 - 09/2004
3SurvivinIBA
03/2009 - 05/2005
3Proteasome InhibitorsIBA
02/2009 - 12/2002
3trifluridine tipiracil drug combinationIBA
10/2008 - 09/2006
3Indicators and Reagents (Reagents)IBA
09/2008 - 07/2005
3EndostatinsIBA
04/2008 - 09/2002
3Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
05/2007 - 12/2004
3Imatinib Mesylate (Gleevec)FDA Link
01/2007 - 11/2005
3BilirubinIBA
07/2006 - 06/2003
3tipifarnib (R115777)IBA
07/2006 - 04/2003
3AEE 788 (AEE788)IBA
11/2005 - 05/2005
3AntibodiesIBA
10/2005 - 09/2002
2Amino AcidsFDA Link
05/2022 - 11/2005
2CarbohydratesIBA
05/2022 - 07/2010
2Reactive Oxygen Species (Oxygen Radicals)IBA
01/2021 - 01/2019
2Superoxides (Superoxide)IBA
01/2019 - 06/2004
2ImmunosorbentsIBA
01/2017 - 12/2004
2PlatinumIBA
09/2015 - 09/2008

Therapy/Procedure

81Therapeutics
01/2022 - 04/2002
33Drug Therapy (Chemotherapy)
09/2015 - 01/2002
16Pancreaticoduodenectomy
11/2020 - 05/2002
14Radiotherapy
01/2022 - 04/2002
9Neoadjuvant Therapy
12/2013 - 04/2006
4Oral Administration
08/2011 - 07/2005
4Chemoradiotherapy
02/2011 - 04/2009
4Lasers (Laser)
07/2010 - 12/2002
3Chemoprevention
11/2010 - 10/2003
3Aftercare (After-Treatment)
02/2009 - 01/2004
2Adjuvant Chemotherapy
11/2020 - 05/2010